MSc dissertation · Jan 2025 – Sep 2025
Bevacizumab–PLGA Nanoparticle Conjugates
Up to 43%more antibody attached at an optimised 1:1 molar ratio
Compared maleimide and carbodiimide (EDC/NHS) conjugation for an antibody–PLGA active-targeting system. Fabricated 2% PLGA nanoparticles by electrospray (450 ± 63 nm by SEM), showed maleimide chemistry gave superior antibody binding by ELISA and DLS, and validated low-temperature storage over 2 months as best for charge stability and antibody activity.
- Electrospray
- SEM
- ELISA
- DLS
- Maleimide
- EDC/NHS
MSc project · Aug 2024 – Jan 2025
3D-Printed Sorafenib Tablets
200–400 mgprecise, clinically relevant doses
Developed oral tablets of the poorly soluble anti-cancer drug sorafenib tosylate by semi-solid extrusion (SSE) 3D printing, for flexible dosing and controlled release. Optimised a PVPK30/HPMC/PEG400 matrix (10:8:8), confirmed 70% amorphisation, and measured release kinetics by HPLC-based in vitro dissolution testing.
- SSE 3D printing
- Rheometry
- FTIR
- P-XRD
- DSC
- HPLC
Undergraduate research · Nov 2023 – Aug 2024
Anti-SARS-CoV-2 Nanobody C5 Trimer Structure
5concentrations analysed for receptor/nanobody binding ratio
Collected X-ray scattering (SAXS) data at the Diamond Light Source synchrotron and combined it with AlphaFold modelling. Purified the C5 trimer on an ÄKTA system, used analytical ultracentrifugation sedimentation velocity to determine molecular weight and binding ratios, and confirmed molecular mass by mass spectrometry.
- SAXS
- AlphaFold
- ÄKTA
- AUC
- Mass spectrometry
Course project · Jan 2024 – Jun 2024
Physicochemical Characterisation of Formulations
Characterised MAN/PVP films and freeze-dried powders at different ratios, analysing crystallinity, thermal stability and hydrogen bonding.